Organic Dental repair prompted by Alzheimer’s drug

A thorough study of the drug Tideglusib is being conducted. It is an inhibitor of the glycogen synthase kinase GSK-3. Researchers theorize that its use will counteract cellular degradation and neurodegeneration that leads to Alzheimer’s disease and other diseases leading to neuron loss, and spatial memory deterioration. However, the drug has proven surprising results, particularly in the dental industry.



A five-month evaluation looked at safety, effects on cognitive ability and mood. Test centers in Spain, Germany and other European countries compared dosages measured against placebos. In a rush, the FDA is on a fast track to progress the release of the new drug.

In fact, another progressive disease called PSP or progressive supranuclear palsy is more closely related to Parkinson’s disease. The FDA along with Noscira (the new name for Neuropharma) was pushing for its release in the treatment of these ailments.


Video (Reuters):


FDA pushing release of new drug for clinical dental treatment

In addition to Alzheimer’s, testing was also meant for the application of Tideglusib in the treatment of PSP. Distribution of a daily dose of 600 or 800 mg against a placebo was handed out to patients. Although some inflammation reduction was noted, the drug’s potency against both Alzheimer’s and PSP showed negative results. Moreover, these outcomes were based on the drug’s primary intention.

However, notably, the drug had other redeeming value. Patients and researchers noticed a change in reparative dental vitality. A dentine formation stimulates vital pulp essential to strong, healthy teeth and gums was a side effect of Tideglusib, after only six weeks of treatment. Dentine is the natural organic substance our bodies manufacture to fight tooth decay.



Somewhere in the chemistry of Tideglusib, an enzyme prompts dentine to resume manufacture and resulting in repair of tooth decay and cavities.


Noticeable evidence of c within six weeks

The study included a team inserting small biodegradable sponges soaked with Tideglusib into the cavities of mice. Within six weeks dentine growth increased leaving the teeth healthy as the sponges melted away. The objective now is to make this clinical dental product immediately available. The natural dental treatment is innovative and boldly effective. Taking the synthetic enzyme and introducing it to tooth decay, showed unbelievable acceleration of the body’s own defenses. In this case, Dentine formed. Significant healing resulted from GSK-3.



Hopefully, the impact on Alzheimer’s disease, Parkinson’s or Progressive Supranuclear Palsy will not be detrimental in the process. Meanwhile, the GSK-3 inhibitor has shown promise in dental health exponentially. Researchers and FDA are striving towards the next phase in this clinical dental treatment release.


More testing is inevitable

Additionally, there remains more testing that must be studied. The effects of this drug have shown some potential anti-inflammatory effect. It also helped improve slight spatial memory deficits. Whether any action on the histopathological lesions or accumulation of plaques in the brain or neuron losses occurs, remains to be seen. Furthermore, in regards to an Alzheimer’s treatment Tideglusib remains a mystery. On the dental front, all systems are ready to go.


References: Futurism, New Drug Approvals, Scientific Reports

Image credit: rgerber/